Abituzumab
Based on 1 Customer Validation
Abituzumab (DI17E6) is a humanised anti-integrin αV monoclonal antibody (IgG2 type). Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.38%
- CAS No.: 1105038-73-0
- Masse moléculaire:144.58 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Human IgG2 kappa
Human
Integrin aV/ITGAV/CD51
Abituzumab (DI17E6) (0.01, 0.1, 1, 10, 30,100 μg/mL; 24 h) inhibits adhesion of PCa cells to multiple extracellular matrix proteins but not collagen I[1]
Abituzumab (100 μg/mL; 12, 18 h) inhibits inhibits motility and invasion of PCa cells[1].
Abituzumab (0.01, 0.1, 1, 10, 30,100 μg/mL; 24 h) inhibits the ability of PCa cells to adhere to osteoblast and bone stromal cell lines[1].
Abituzumab (100 μg/mL; 24 h) blocks integrin-mediated cell signaling in PCa cancer cell lines[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:PCa cells
-
Concentration:0.01, 0.1, 1, 10, 30,100 µg/mL
-
Incubation Time:24 h
-
Result:Promoted detachment of PCa cells from vitronectin (up to approximately 20% cells detached at 100 μg/mL), osteopontin (up to approximately 10% cells detached at 100 μg/mL) and fibronectin (up to approximately 10% cells detached at 100 μg/mL) but not from collagen I.
-
Cell Line:PCa cells
-
Concentration:100 µg/mL
-
Incubation Time:12, 18 h
-
Result:Inhibited invasive ability by approximately 25 to 30% compared to vehicle, and inhibited motility by approximately 30 to 40%.
-
Cell Line:PCa, hFOB, Saos2, HS-5, HDMEC cells
-
Concentration:0.01, 0.1, 1, 10, 30,100 µg/mL
-
Incubation Time:24 h
-
Result:Inhibited PCa cells adhesion to human osteoblast cell lines hFOB and Saos2 and a bone marrow stromal cell line, HS-5.
Promoted detachment of PCa cells from to a known expressor of αv integrins, HDMEC cells.
-
Cell Line:PC3, DU145, C4-2B, LNCaP, ARCaP and VCaP cells
-
Concentration:100 µg/mL
-
Incubation Time:24 h
-
Result:Inhibited FAK phosphorylation starting at 12 h and 6 h in C4-2B and LNCaP, respectively; AKT phosphorylation starting at 3 h and 2 h in C4-2B and LNCaP, respectively; and ERK phosphorylation at starting at 1 h and 1.5 h in C4-2B and LNCaP, respectively.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG2 kappa
ELISA, FACS, Functional assay
-
Immobilized Integrin alpha V beta 3 Protein, Human (HEK293, His, solution, HY-P73868) can bind Abituzumab. The EC50 for this effect is 4.5 ng/mL. -
Flow cytometric analysis of 1X106 A549 cells with Abituzumab (HY-P99183, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 1105038-73-0
-
Appearance Liquid
-
Masse moléculaire 144.58 kDa
-
Color Colorless to light yellow
-
SMILES
[Abituzumab]
-
Synonyms
EMD 525797; DI17E6
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Abituzumab Related Classifications
HY-P99183 Related Classifications
Powered by Bioz